EP3691447A4 - ANTI-TRANSTHYRETINE ANTIBODIES - Google Patents
ANTI-TRANSTHYRETINE ANTIBODIES Download PDFInfo
- Publication number
- EP3691447A4 EP3691447A4 EP18863984.3A EP18863984A EP3691447A4 EP 3691447 A4 EP3691447 A4 EP 3691447A4 EP 18863984 A EP18863984 A EP 18863984A EP 3691447 A4 EP3691447 A4 EP 3691447A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- transthyretin antibodies
- transthyretin
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/603—Salicylic acid; Derivatives thereof having further aromatic rings, e.g. diflunisal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/65—Tetracyclines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762569436P | 2017-10-06 | 2017-10-06 | |
US201762598965P | 2017-12-14 | 2017-12-14 | |
PCT/US2018/054720 WO2019071205A1 (en) | 2017-10-06 | 2018-10-05 | ANTI-TRANSTHYRETIN ANTIBODY |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3691447A1 EP3691447A1 (en) | 2020-08-12 |
EP3691447A4 true EP3691447A4 (en) | 2021-08-11 |
Family
ID=65994817
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18863984.3A Pending EP3691447A4 (en) | 2017-10-06 | 2018-10-05 | ANTI-TRANSTHYRETINE ANTIBODIES |
Country Status (14)
Country | Link |
---|---|
US (1) | US11267877B2 (zh) |
EP (1) | EP3691447A4 (zh) |
JP (1) | JP7357609B2 (zh) |
KR (1) | KR20200074956A (zh) |
CN (1) | CN111315213B (zh) |
AU (1) | AU2018345806A1 (zh) |
BR (1) | BR112020006434A2 (zh) |
CA (1) | CA3077361A1 (zh) |
CU (1) | CU20200021A7 (zh) |
MX (1) | MX2020003041A (zh) |
PE (1) | PE20210552A1 (zh) |
SG (1) | SG11202002489YA (zh) |
WO (1) | WO2019071205A1 (zh) |
ZA (1) | ZA202002141B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
WO2019071205A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
CN111433223A (zh) | 2017-11-29 | 2020-07-17 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白单克隆抗体的冻干制剂 |
KR20230009950A (ko) | 2020-05-12 | 2023-01-17 | 뉴리뮨 아게 | Ttr 아밀로이드증에 대한 조합 치료법 |
WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
TW202346340A (zh) * | 2022-04-20 | 2023-12-01 | 美商聖堤生物科技股份有限公司 | 抗原結合域及其使用方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2044443A2 (en) * | 2006-07-03 | 2009-04-08 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
US20140056904A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Antibodies to TTR and Methods of Use |
WO2014124334A2 (en) * | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
CA2404237C (en) | 2000-04-05 | 2010-01-26 | University Of Tennessee Research Corporation | Methods of investigating, diagnosing, and treating amyloidosis |
AU2003270643A1 (en) | 2002-09-12 | 2004-04-30 | The Regents Of The University Of California | Immunogens and corresponding antibodies specific for high molecular weight aggregation intermediates common to amyloids formed from proteins of differing sequence |
WO2010011999A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Methods and compositions for eliciting an amyloid-selective immune response |
WO2010012004A2 (en) | 2008-07-25 | 2010-01-28 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyoid aggregates common to amyloids formed from proteins of differing sequence |
WO2005025516A2 (en) | 2003-09-12 | 2005-03-24 | The Regents Of The University Of California | Monoclonal antibodies specific for conformational epitopes of prefibrillar aggregates |
US20110200609A1 (en) | 2002-09-12 | 2011-08-18 | The Regents Of The University Of California | Monoclonal antibodies specific for pathological amyloid aggregates common to amyloids formed from proteins of differing sequence |
WO2006108234A1 (en) * | 2005-04-13 | 2006-10-19 | Garvan Institute Of Medical Research | Modified animal lacking functional pyy gene, monoclonal antibodies that bind pyy isoforms and uses therefor |
EP2502999A3 (en) | 2006-03-03 | 2013-01-23 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
EP2548647B1 (en) | 2006-10-20 | 2018-08-15 | CLONDIAG GmbH | Assay devices and methods for the detection of analytes |
WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
EP2342220B1 (en) | 2008-10-06 | 2021-05-12 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
CA2753621A1 (en) | 2009-03-02 | 2010-09-10 | The University Of British Columbia | Antibodies and epitopes specific to misfolded prion protein |
TWI667257B (zh) | 2010-03-30 | 2019-08-01 | 中外製藥股份有限公司 | 促進抗原消失之具有經修飾的FcRn親和力之抗體 |
FI20115165A0 (fi) | 2011-02-21 | 2011-02-21 | Polysackaridforskning I Uppsala Ab | Terapeuttisia ja diagnostisia menetelmiä |
EP2679681B2 (en) | 2011-02-25 | 2023-11-15 | Chugai Seiyaku Kabushiki Kaisha | FcgammaRIIB-specific FC antibody |
EP2698431B1 (en) | 2011-03-30 | 2020-09-09 | Chugai Seiyaku Kabushiki Kaisha | Retention of antigen-binding molecules in blood plasma and method for modifying immunogenicity |
TW201817744A (zh) | 2011-09-30 | 2018-05-16 | 日商中外製藥股份有限公司 | 具有促進抗原清除之FcRn結合域的治療性抗原結合分子 |
DK2857419T3 (da) | 2012-05-30 | 2021-03-29 | Chugai Pharmaceutical Co Ltd | Antigen-bindende molekyle til eliminering af aggregerede antigener |
UA118441C2 (uk) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Антитіло, що розпізнає альфа-синуклеїн |
WO2014142334A1 (ja) * | 2013-03-12 | 2014-09-18 | 国立大学法人名古屋大学 | 植物の光合成および生産量を増加させる方法 |
US20160168235A1 (en) | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
CN106255702B (zh) | 2013-12-20 | 2020-03-24 | 生物控股有限公司 | 基于抗体的对转甲状腺素蛋白(ttr)淀粉样变性的疗法及其人源抗体 |
EP3101131B1 (en) | 2014-01-29 | 2020-08-19 | KM Biologics Co., Ltd. | Anti-transthyretin humanized antibody |
KR102240417B1 (ko) | 2014-01-29 | 2021-04-13 | 케이엠 바이올로직스 가부시키가이샤 | 항-트랜스티레틴 인간 항체 |
HUE059857T2 (hu) | 2014-08-29 | 2023-01-28 | Alnylam Pharmaceuticals Inc | Patizirán transztiretin által közvetített amiloidózis kezelésében történõ alkalmazásra |
TWI761959B (zh) | 2014-11-07 | 2022-04-21 | 瑞士商諾華公司 | 治療眼部疾病之方法 |
US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI711631B (zh) * | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI781507B (zh) | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
TWI786505B (zh) | 2015-01-28 | 2022-12-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
EP3478715A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3478714A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
EP3478716A2 (en) | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
JP7292569B2 (ja) | 2017-10-06 | 2023-06-19 | ノボ ノルディスク エー/エス | トランスサイレチンを検出する方法 |
WO2019071205A1 (en) | 2017-10-06 | 2019-04-11 | Prothena Biosciences Limited | ANTI-TRANSTHYRETIN ANTIBODY |
CN111433223A (zh) | 2017-11-29 | 2020-07-17 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白单克隆抗体的冻干制剂 |
WO2021168156A1 (en) | 2020-02-20 | 2021-08-26 | Prothena Biosciences Limited | Monitoring transthyretin amyloidosis |
-
2018
- 2018-10-05 WO PCT/US2018/054720 patent/WO2019071205A1/en active Application Filing
- 2018-10-05 KR KR1020207012722A patent/KR20200074956A/ko not_active Application Discontinuation
- 2018-10-05 CU CU2020000021A patent/CU20200021A7/es unknown
- 2018-10-05 US US16/753,307 patent/US11267877B2/en active Active
- 2018-10-05 JP JP2020518649A patent/JP7357609B2/ja active Active
- 2018-10-05 AU AU2018345806A patent/AU2018345806A1/en active Pending
- 2018-10-05 BR BR112020006434-3A patent/BR112020006434A2/pt unknown
- 2018-10-05 PE PE2020000481A patent/PE20210552A1/es unknown
- 2018-10-05 MX MX2020003041A patent/MX2020003041A/es unknown
- 2018-10-05 SG SG11202002489YA patent/SG11202002489YA/en unknown
- 2018-10-05 EP EP18863984.3A patent/EP3691447A4/en active Pending
- 2018-10-05 CA CA3077361A patent/CA3077361A1/en active Pending
- 2018-10-05 CN CN201880071788.1A patent/CN111315213B/zh active Active
-
2020
- 2020-05-04 ZA ZA2020/02141A patent/ZA202002141B/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2044443A2 (en) * | 2006-07-03 | 2009-04-08 | The Johns Hopkins University | Peptide antibody depletion and its application to mass spectrometry sample preparation |
US20140056904A1 (en) * | 2012-08-24 | 2014-02-27 | University Health Network | Antibodies to TTR and Methods of Use |
WO2014124334A2 (en) * | 2013-02-08 | 2014-08-14 | Misfolding Diagnostics, Inc. | Transthyretin antibodies and uses thereof |
Non-Patent Citations (1)
Title |
---|
JEFFREY N. HIGAKI ET AL: "Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin", AMYLOID, vol. 23, no. 2, 16 March 2016 (2016-03-16), GB, pages 86 - 97, XP055372418, ISSN: 1350-6129, DOI: 10.3109/13506129.2016.1148025 * |
Also Published As
Publication number | Publication date |
---|---|
CN111315213A (zh) | 2020-06-19 |
JP2020536532A (ja) | 2020-12-17 |
US11267877B2 (en) | 2022-03-08 |
CU20200021A7 (es) | 2021-01-12 |
AU2018345806A1 (en) | 2020-03-12 |
CA3077361A1 (en) | 2019-04-11 |
WO2019071205A1 (en) | 2019-04-11 |
BR112020006434A2 (pt) | 2020-11-03 |
JP7357609B2 (ja) | 2023-10-06 |
EP3691447A1 (en) | 2020-08-12 |
MX2020003041A (es) | 2020-10-05 |
ZA202002141B (en) | 2023-01-25 |
CN111315213B (zh) | 2023-09-12 |
PE20210552A1 (es) | 2021-03-17 |
US20200331992A1 (en) | 2020-10-22 |
SG11202002489YA (en) | 2020-04-29 |
KR20200074956A (ko) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3589313A4 (en) | ANTI-TIGITE ANTIBODY | |
EP3481869A4 (en) | ANTI-CD73 ANTIBODY | |
EP3498840A4 (en) | ANTI-LAG-3 ANTIBODIES | |
EP3569709A4 (en) | ANTI-GPC3 ANTIBODIES | |
LT3606954T (lt) | Anti-lag3 antikūnai | |
EP3334757A4 (en) | ANTI-TIGIT ANTIBODIES | |
EP3297671A4 (en) | ANTI-ROR1 ANTIBODY | |
EP3387442A4 (en) | HUMANIZED ANTI-CD73 ANTIBODIES | |
EP3503920A4 (en) | ANTI-CTLA4 ANTIBODIES | |
EP3354729A4 (en) | ANTI-GARP ANTIBODY | |
EP3661558A4 (en) | ANTI-IL1RAP ANTIBODIES | |
EP3606961B8 (en) | Garp-tgf-beta antibodies | |
EP3684806A4 (en) | NEW ANTI-CD3EPSILON ANTIBODIES | |
EP3380524A4 (en) | HUMANIZED ANTI-CLL-1 ANTIBODIES | |
EP3492591A4 (en) | ANTI-B7-H4 ANTIBODIES | |
EP3522922A4 (en) | NEW ANTI-CTLA4 ANTIBODIES | |
EP3252074A4 (en) | Anti-alk2 antibody | |
EP3617231A4 (en) | ANTI-GPC-1 ANTIBODY | |
EP3691447A4 (en) | ANTI-TRANSTHYRETINE ANTIBODIES | |
EP3596126A4 (en) | NEW ANTI-TRKB ANTIBODIES | |
EP3507307A4 (en) | BISPECIFIC ANTIBODIES | |
EP3349794A4 (en) | ANTI-CD115 ANTIBODIES | |
EP3526247A4 (en) | ANTI-IL1 RAP ANTIBODIES | |
EP3381941A4 (en) | ANTI-EPHA4 ANTIBODY | |
EP3831851A4 (en) | ANTI-BTLA ANTIBODIES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20200225 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40035184 Country of ref document: HK |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20210712 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A01K 67/027 20060101AFI20210706BHEP Ipc: A61K 31/713 20060101ALI20210706BHEP Ipc: A61K 38/17 20060101ALI20210706BHEP Ipc: A61K 39/395 20060101ALI20210706BHEP Ipc: A61K 49/00 20060101ALI20210706BHEP |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: NOVO NORDISK A/S |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |